Affimed NV

AFMD60

Penny Stock

$3.69arrow_drop_down6.81%-$0.27

Penny Stock

AFMD60

$3.69

arrow_drop_down6.81%-$0.27

Penny Stock

Performance History

Key Stats
Open	$3.90
Prev. Close	$3.96
EPS	-5.85
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-
Market Cap	$57.86M
PE Ratio	-

	LOW	HIGH
Day Range	3.65	3.98
52 Week Range	2.24	8.95

Ratios







EPS	-5.85

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Affimed NV (AFMD)

Affimed NV (NASDAQ: AFMD) is a clinical-stage biopharmaceutical company that focuses on discovering and developing highly targeted cancer immunotherapies. The company's proprietary platform, called ROCK®, enables it to generate and optimize a novel class of antibodies called tetravalent bispecific antibodies. These antibodies are designed to direct the patient's immune system to specifically target and destroy tumor cells. Affimed NV's lead drug candidate, AFM13, is currently in clinical trials for the treatment of patients with CD30-positive lymphomas. Additionally, the company is developing other immune cell engagers, NK cell engagers, and tumor-targeted antibodies for the treatment of various cancers.

As of October 20, 2021, the stock price of Affimed NV (AFMD) is $10.76 per share. The 52-week range for AFMD is $2.50 to $25.40. The day's trading volume is 1,049,936 shares. The market capitalization of Affimed NV is $676.45 million. When comparing AFMD to its industry, it is important to note that the stock has performed significantly better than its peers. The PEG ratio of Affimed NV is not available at this time. However, the company's strong pipeline and innovative platform have attracted investors' attention, leading to a positive outlook for the stock.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Dr. Adi Hoess M.D., Ph.D.
Headquarters: Heidelberg
Employees: 219
Exchange: NASDAQ

Keep an eye on Affimed NV

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

Is Affimed NV (AFMD) a growth stock?

Affimed NV (AFMD) has shown an average price growth of 0.41% over the past three years. It has received a score of 95 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Affimed NV as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Affimed NV's (AFMD) price per share?

The current price per share for Affimed NV (AFMD) is $3.69. The stock has seen a price change of -$0.27 recently, indicating a -6.82% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Affimed NV (AFMD)?

For Affimed NV (AFMD), the 52-week high is $8.95, which is 142.55% from the current price. The 52-week low is $2.24, the current price is 64.73% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

What is Affimed NV (AFMD) stock price performance year to date (YTD)?

As of the latest data, Affimed NV (AFMD) has a year-to-date price change of -40.96%. Over the past month, the stock has experienced a price change of -13.38%. Over the last three months, the change has been -37.14%. Over the past six months, the figure is -26.79%. Looking at a longer horizon, the five-year price change stands at -89.49%.

help

Is Affimed NV (AFMD) a profitable company?

Affimed NV (AFMD) has a net income of -$105.94M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -7.41K% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $8.28M, although specific revenue growth data is currently not available. The gross profit is $8.28M. Operating income is noted at -$106.66M. Furthermore, the EBITDA is -$79.45M.

help

What is the market capitalization of Affimed NV (AFMD)?

Affimed NV (AFMD) has a market capitalization of $57.86M. The average daily trading volume is 80.67K, indicating the stock's liquidity and investor engagement.